

Second Edition

Integrated **Pharmaceuticals**

**Applied Preformulation, Product Design,
and Regulatory Science**

Antoine Al-Achi

Mali Ram Gupta

William Craig Stagner



WILEY

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[Dedication Page](#)

[Foreword to Second Edition](#)

[Foreword to First Edition](#)

[Preface to Second Edition](#)

[Acknowledgments](#)

[Preface to First Edition](#)

[Acknowledgments](#)

[About the Companion Website](#)

[Part I: Applied Preformulation](#)

[1 Mathematical Concepts](#)

[1.1 Introduction](#)

[1.2 Significant Figures and Rounding off
Numbers](#)

[1.3 The Simple Linear Relationship](#)

[1.4 Exponential Rules](#)

[1.5 Logarithmic Rules](#)

[1.6 Differential Equations](#)

[1.7 Expanding and Reducing Formulas](#)

[1.8 Weights and Measures](#)

[References](#)

[Glossary](#)

[2 Thermodynamics](#)

[2.1 Introduction](#)

[2.2 The Zeroth Law of Thermodynamics](#)

[2.3 The First Law of Thermodynamics](#)

[2.4 The Second Law of Thermodynamics](#)

[2.5 The Third Law of Thermodynamics](#)

[2.6 Polymorphism](#)

[2.7 Physical Stability of Crystal Forms](#)

[2.8 Solubility](#)

[References](#)

[Glossary](#)

[3 Solubility and Dissolution](#)

[3.1 Introduction](#)

[3.2 Methods of API Solubility Enhancement](#)

[3.3 Nonionic, Ionic, and Acid-Base Concepts
Related to Solubility and Dissolution](#)

[3.4 The Solubility of Gas in Liquid](#)

[3.5 The Solubility of Liquid in Liquid](#)

[3.6 The Solubility of Solid in Liquid](#)

[3.7 Disintegration and Dissolution](#)

[3.8 Concentration Units](#)

[3.9 The Partition Coefficient](#)

[3.10 Concluding Remarks](#)

[References](#)

[Glossary](#)

[Appendix](#)

[4 Biological Aspects of Formulations](#)

[4.1 Introduction](#)

[4.2 Bioavailability and Bioequivalence](#)

[4.3 Protocols for Determining Bioequivalence](#)

[4.4 Bioequivalence Procedure](#)

[4.5 FDA-Approved Methods for Bioequivalence Studies](#)

[4.6 Approaches to Improving Bioavailability](#)

[References](#)

[Glossary](#)

[5 Interfacial Properties](#)

[5.1 Introduction](#)

[5.2 Liquid-Solid Interface](#)

[5.3 Liquid-Liquid Interface](#)

[5.4 Dosage-Form Applications](#)

[5.5 Case Study: HLB Determination](#)

[5.6 Case Study: Determination of Required HLB \(rHLB\)](#)

[References](#)

[Glossary](#)

[6 Adsorption Phenomenon](#)

[6.1 Introduction](#)

[6.2 Adsorption on Filters](#)

[6.3 Adsorption of Proteins](#)

[References](#)

[Glossary](#)

[7 Rheological Principles](#)

[7.1 Introduction](#)

[7.2 Newtonian Systems](#)

[7.3 Non-Newtonian Systems](#)

[7.4 Viscoelasticity](#)

[7.5 Reynolds Number](#)

[7.6 Concluding Remarks](#)

[References](#)

[Glossary](#)

[8 Chemical Stability and Shelf-Life Determination](#)

[8.1 Introduction](#)

[8.2 Shelf-Life Determination](#)

[8.3 Stability of Biotechnology Products](#)

[8.4 Compounded Products and Their Beyond-Use Dates](#)

[References](#)

[Glossary](#)

[9 Particle Science](#)

[9.1 Introduction](#)

[9.2 Miromeritics](#)

[9.3 Micronization](#)

[9.4 Particle Size Preparation and Reduction for Pulmonary Delivery](#)

[9.5 Polymeric Particulate Matter](#)

[9.6 Nanoparticles](#)

[9.7 Segregation of Particles](#)

[9.8 Case Studies: Microscopic Particle Size Analysis, Determining Statistically Valid Sample Size, and Comparison of Sieve and Focused Beam Reflectance Measurement Chord Length Particle Size Distributions](#)

[References](#)

[Glossary](#)

[10 Basic Statistics and Design of Experimental Concepts](#)

[10.1 Descriptive Statistics](#)

[10.2 Inferential Statistics](#)

[10.3 Statistical Applications in Quality Control Testing](#)

[10.4 Design of Experiment](#)

[10.5 Multivariate Analysis \(MVA\)](#)

[10.6 Reliability and Validity Assessment](#)

[References](#)

[Glossary](#)

[11 Formulation Development Concepts](#)

[11.1 Preformulation](#)

[11.2 Scale-up Considerations](#)

[11.3 Combination Products](#)

[11.4 Rate-Controlled Drug Delivery](#)

[11.5 Drug Delivery Technologies for Improving Oral Delivery](#)

[11.6 Drug Delivery Technologies for Improving Transmucosal Delivery](#)

[11.7 Drug Delivery Technologies for Transdermal Delivery](#)

[11.8 Special Considerations for Biotechnology and Protein Delivery Systems](#)

[11.9 Drug-Excipient and Excipient-Excipient Interactions](#)

[11.10 The Presence of Contaminants in a Formulation](#)

[11.11 Other Considerations](#)

[References](#)

[Glossary](#)

[Part II: Product Design](#)

[12 The Product Design Process](#)

[12.1 Introduction](#)

[12.2 Formulation Design](#)

[12.3 Process Design](#)

[12.4 Container Closure System Design](#)

[References](#)

[Glossary](#)

[12.A Appendix](#)

[13 Tablet Product Design](#)

[13.1 Introduction](#)

[13.2 Formulation Design](#)

[13.3 Process Design](#)

[13.4 Container Closure System Design](#)

[13.5 Risk Management](#)

[13.6 Attribute Tests](#)

[13.7 New Drug Application Stability Assessment](#)

[References](#)

[Glossary](#)

[13.A Appendix](#)

[14 Capsule Product Design](#)

[14.1 Introduction](#)

[14.2 Hard-Shell Capsules](#)

[14.3 Soft-Shell Capsules](#)

[14.4 Formulation and Process Optimization](#)

[14.5 Container Closure System Design](#)

[14.6 Risk Management](#)

[14.7 Attribute Tests](#)

[14.8 New Drug Application Stability Assessment](#)

[References](#)

[Glossary](#)

[14.A Appendix](#)

[15 Dispersed System Product Design](#)

[15.1 Introduction](#)

[15.2 Formulation Design](#)

[15.3 Process Design](#)

[15.4 Container Closure System Design](#)

[15.5 Risk Management](#)

[15.6 Attribute Tests](#)

[15.7 New Drug Application Stability Assessment](#)

[References](#)

[Glossary](#)

[Appendices](#)

[16 Aerosol Product Design](#)

[16.1 Introduction](#)

[16.2 Inhalation Formulation Design](#)

[16.3 Nasal, Buccal, Lingual, and Sublingual Aerosol Formulation Design](#)

[16.4 Container Closure System Design](#)

[16.5 Risk Management](#)

[16.6 Attribute Tests](#)

[16.7 New Drug Application Stability Assessment](#)

[References](#)

[Glossary](#)

[16.A Appendix](#)

[17 Sterile Injectable Product Design](#)

[17.1 Introduction](#)

[17.2 Formulation Design](#)

[17.3 Process Design](#)

[17.4 Container Closure System Design](#)

[17.5 Risk Management](#)

[17.6 Attribute Tests](#)

[17.7 New Drug Application Stability Assessment](#)

[References](#)

[Glossary](#)

[17.A Appendix](#)

[18 Ophthalmic Product Design](#)

[18.1 Introduction - Eye Anatomy and Physiology](#)

[18.2 Formulation Design](#)

[18.3 Process Design](#)

[18.4 Container Closure System Design](#)

[18.5 Attribute Tests](#)

[18.6 New Drug Application Stability Assessment](#)

[References](#)

[Glossary](#)

[18.A Appendix](#)

[19 Transdermal Product Design](#)

[19.1 Introduction - Skin Anatomy and Physiology](#)

[19.2 Formulation Design](#)

[19.3 Conclusions](#)

[References](#)

[Glossary](#)

[19.A Appendix](#)

[20 Oral Modified-Release Product Design](#)

[20.1 Introduction](#)

[20.2 FDA and U.S.P. Nomenclature](#)

[20.3 Modified-Release Mechanisms](#)

[20.4 *In Vitro-In Vivo* Correlations \(IVIVC\)](#)

[20.5 Coatings](#)

[20.6 Matrix Systems](#)

[20.7 Gastroretentive Devices](#)

[20.8 Osmotic-Controlled Release Systems](#)

[20.9 Conclusions](#)

[References](#)

[Glossary](#)

[20.A Appendix](#)

[Part III: Regulatory Science](#)

[21 Regulatory Practices and Guidelines](#)

[21.1 Worldwide Regulatory Agencies](#)

[21.2 Good Manufacturing Practice \(GMP\)](#)

[21.3 FDA Inspection and Regulatory Actions \(FDA 2020b, 2020d\)](#)

[References](#)

[Glossary](#)

[21.A Appendix](#)

[22 Regulations for Compounding Pharmacies](#)

[22.1 Introduction](#)

[22.2 Sections 503A and 503B and Their Differences \(FDA 2018a\)](#)

[22.3 Compounding Guidelines](#)

[22.4 Good Compounding Practices \(FDA 2007; Skoloff 2009; U.S.P. <795> 2020; U.S.P. <797> 2020\); U.S.P. <1191> 2018; USP29 2006; USP29NF24 2006; OSBP 2017; NDBOPH 2020; NV 2020a; OR 2020; CPE 2017; OK 2020; KY 2016a; WA 2020a; FDA 2020a, 2020b\).](#)

[22.5 Compounding Sterile Preparations \(U.S.P. <797> 2020; WA 2020b; CT 2020; OR 2020; NV 2020b; OK 2020; KY 2016b; NYBOP \(n.d.\); ASPH 2003, 2020; TU n.d.\)](#)

[22.6 Stability Criteria and Beyond-Use Dating of Compounded Non-Sterile Preparations \(U.S.P. <797> 2020; WA 2020b; CT 2020; OR 2020; NV 2020b; OK 2020; KY 2016b; NYBOP \(n.d.\); ASPH 2003, 2020; TU n.d.\)](#)

[22.7 Verification \(U.S.P. <795> 2020; U.S.P. <797> 2020; WA 2020a, 2020b\)](#)

[22.8 Patient Counseling \(U.S.P. <795> 2020; U.S.P. <797> 2020; WA 2020a, 2020b\)](#)

[22.9 Patient Monitoring and Adverse Events Reporting \(U.S.P. <797> 2020; WA 2020b\)](#)

[22.10 Pharmacy Compounding Accreditation](#)

[22.11 Compounding: Inspections, Recalls, and Other Actions \(FDA 2018b; FDA 2018c\)](#)

[References](#)

[Glossary](#)

[22.A Appendix](#)

[23 IND and NDA Phase-Appropriate New Drug Development Process](#)

[23.1 Introduction](#)

[23.2 Preclinical Development Overview \(FDA 1998\)](#)

[23.3 Phase-Appropriate Clinical Trials Overview \(FDA 1998\)](#)

[23.4 Investigational New Drugs](#)

[23.5 Good Laboratory Practice for Nonclinical Laboratories Studies \[21CFR58\] \(FDA 2020c\)](#)

[23.6 CGMP for Phase 1 Investigational Drugs – Guidance for Industry \(FDA 2008\)](#)

[23.7 Good Clinical Practice \[E6\(R2\)\] Guidance for Industry \(FDA 2016, 2018b, 2019a\)](#)

[23.8 NDA Review Process \(FDA 1998\)](#)

[References](#)

[Glossary](#)

[23.A Appendix](#)

[24 Biological, Biosimilar, Generic, and OTC Products](#)

[24.1 Biologicals \(FDA 2015a, 2015b, 2016b, 2018a, 2018b, 2019a, 2019b, 2019c, 2020a; EMA 2019\)](#)

[24.2 Biosimilars \(EMA n.d.-a, n.d.-b; FDA n.d.-a, n.d.-b; Christl n.d.; FDA n.d.-c; Lim n.d., 2013; FDA 2017a, 2017b, 2017c, 2018c, 2020b, 2020c; EMA 2019\)](#)

[24.3 Generic Drugs \(FDA 1998a, 2014b, 2017f, 2017g, 2018e, 2018g, 2019d\)](#)

[24.4 Over-the-Counter Drugs \(FDA 1998b, 2016a, 2018g, 2019f, 2020e, 2020f, 2020g\)](#)

[References](#)

[Glossary](#)

[24.A Appendix](#)

[25 Accelerated New Drug Approval and Expedited Access of New Therapies](#)

[25.1 Introduction](#)

[25.2 Expedited Review and Approval of New Therapies \(HIV n.d.; IOM 1991; FDA 2009a, 2010a, 2011b, 2014\)](#)

[25.3 Expanded Access to New Therapies \(HIV n.d.; FDA 2009a\)](#)

[25.4 Orphan Drugs \(EMA n.d.-a, n.d.-b; WebMD n.d.; FDA 1998a, 2005a, 2018, 2018b, 2020c; IOM 2010\)](#)

[25.5 Pediatric Drugs \(FDA 1998b, 2005b\)](#)

[25.6 Pediatric Drug Development and the Orphan Drug Act Incentives \(FDA 2010c\)](#)

[25.7 Common EMEA/FDA Application for Orphan Medicinal Product Designation \(EMA n.d.-a, n.d.-b; FDA 2009b; FDA 2018\)](#)

[References](#)

[Glossary](#)

[26 Post-Drug Approval Activities](#)

[26.1 Postmarket Requirements and Commitments \(FDA 2016b, 2018f, 2020a, 2020e\)](#)

[26.2 Postapproval Manufacturing Changes \(FDA 2018d, 2020b\)](#)

[26.3 Clinical Phase 4 Studies: Postmarketing Surveillance and Risk Assessment \(FDA 2018d, 2019b\)](#)

[26.4 Prescription Drug Advertising and Promotional Labeling Direct to Consumers \(FDA 1998c\)](#)

[References](#)

[Glossary](#)

[26.A Appendix](#)

[27 Drug Master Files, EU Dossiers, and API GMP Guidance](#)

[27.1 Drug Master Files \(FDA 2001, 2011a, 2011b, 2011c, 2011d, 2011e\)](#)

[27.2 European Marketing Authorization Dossiers](#)

[27.3 Good Manufacturing Practice \(GMP\) Guidance for Active Pharmaceutical Ingredients \(Q7\) \(FDA 2016\)](#)

[References](#)

[Glossary](#)

[28 Commissioning and Qualification](#)

[28.1 Regulatory Requirements \(Health Canada 2009; EU 2015; FDA 2017, 2018a, 2020\)](#)

[28.2 Preliminary C&Q Activities](#)

[28.3 Commissioning](#)

[28.4 Qualification and Validation](#)

[28.5 Qualification Protocols \(ISPE 2001; Health Canada 2009; PIC/S 2018\)](#)

[28.6 Process Validation \(FDA 2014, 2019; PIC/S 2018\)](#)

[28.7 Cleaning Validation \(Health Canada 2008; FDA 2014, 2017; PIC/S 2018\)](#)

[28.8 Computer Systems Validation \(ISPE 2001; EU 2011\)](#)

[28.9 Change Control \(EU 2015; PIC/S 2018\)](#)

[28.10 Revalidation \(CDRH 1995; EU 2015; FDA 2015; PIC/S 2018\)](#)

[References](#)

[Glossary](#)

29 Quality Systems and Controls

29.1 Pharmaceutical Quality System (FDA 2019a)

29.2 Quality Systems Approach to CGMP Regulations

29.3 Inspection of Pharmaceutical Quality Control Laboratories (FDA 2014)

29.4 Pharmacopeias (U.S.P. 2014)

29.5 Analytical Instrument Qualification (U.S.P. <1058> 2019a; FDA 2010)

29.6 Validation of Analytical Procedures (U.S.P. <1225> 2019b; FDA 2000, 2015, 2019b)

29.7 Stability Testing of New Drug Substances and Products (U.S.P. <1150> 2006; ICH 1996; FDA 2018b, 2018c, 2018d)

29.8 Electronic Records; Electronic Signatures (Part 11) (FDA 2019)

References

Glossary

29.A Appendix

30 Safety, Toxicology, and Pharmacogenomics

30.1 Nonclinical Safety Studies (ICH 2009; FDA 2010)

30.2 Safety Pharmacology Studies (ICH 2000)

30.3 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals - (FDA 1997; EMA 2011a)

30.4 Carcinogenicity Studies of Pharmaceuticals (ICH 1995)

30.5 Genotoxicity Testing (ICH 1998, 2008)

30.6 Immunotoxicity Studies (ICH 2005b)

[30.7 Safety Reporting Requirements](#)

[30.8 Pharmacogenomics \(NIGMS 2005; ICH 2005b; ORNL 2010\)](#)

[30.9 Pharmacovigilance \(EMA 2011b, 2015, 2021; Eudra n.d.; FDA 2005c, 2005d\)](#)

[30.10 FDA's Predictive Toxicology Roadmap \(FDA 2017, 2020\)](#)

[References](#)

[Glossary](#)

[Appendix](#)

[31 Regulatory Science Initiatives for Advancing Public Health](#)

[31.1 Introduction](#)

[31.2 Advancing Regulatory Science for Public Health - A Framework for FDA's Regulatory Science Initiatives \(FDA 2010\)](#)

[31.3 Advancing Regulatory Science at FDA - A Strategic Plan \(FDA 2018b, 2018c, 2018d, 2018e, 2018f, 2018g, 2018h, 2018i, 2018j, 2018k, 2018l\)](#)

[31.4 A Collaborative Implementation Framework \(FDA 2010, 2011, 2018n\)](#)

[References](#)

[32 Medical Devices](#)

[32.1 Introduction \(FDA 2018a, 2019a, 2020a\)](#)

[32.2 Device Determination Steps \(FDA 2019a, 2020a\)](#)

[32.3 Classification and Regulatory Requirements \(FDA 2018b, 2020b\)](#)

[32.4 Current Good Manufacturing Practices \(CGMPs\) and Quality System Regulation \(QSR\)](#)

Regulation) Requirements

32.5 Medical Device Complaint Reporting and Recalls (FDA 2019h, 2019i).

References

Glossary

33 Combination Products

33.1 Introduction (FDA 2018, 2019e, 2020).

33.2 Product Jurisdiction/Assignment of Combination and Non-Combination Products (FDA 2019a, 2020).

33.3 Premarket and Marketing Applications (21 CFR Parts 312 and 812) (FDA 2019b, 2019c, 2020).

33.4 Current Good Manufacturing Practice - Subpart A (21CFR4) (FDA 2019d).

33.5 Postmarketing Safety Reporting for Combination Products [21CFR4/Part 4 Regulation of Combination Products/Subpart B] (FDA 2019d).

References

33.A Appendix

34 Dietary Supplements

34.1 Introduction (FDA 2017a, 2019a, 2019b).

34.2 Dietary Ingredients (FDA 2019a, 2019b, 2019c).

34.3 Dietary Supplement Ingredient Advisory List (FDA 2019d).

34.4 DS Labeling: Claims Types and Requirements (FDA 2017b, 2018, 2019e).

34.5 Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or

[Holding Operations for Dietary Supplements \(21 CFR Part 111\)_\(FDA 2019f\).](#)

[34.6 FDA Inspection and Regulatory Actions \(see - 21.3 FDA Inspection and Regulatory Actions - see Chapter 21 for details\).](#)

[References](#)

[Glossary \(specific terms for DS\).](#)

[34.A Appendix](#)

[35 Animal Drugs and Devices](#)

[35.1 FDA Center For Veterinary Medicine \(CVM\)_\(FDA 2019a\).](#)

[35.2 Animal Drug Availability Act of 1996 \(FDA 2019b\).](#)

[35.3 Development and Approval Process \(FDA 2017, 2020a\).](#)

[35.4 CGMP and Others Compliance Requirements](#)

[35.5 Animal Drug Manufacturing Inspection - Pre-Approval \(FDA 2006\).](#)

[35.6 PostMarketing Surveillance \(FDA 2017, 2019d, 2020a\).](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 3

[Table 3.1 Maximum daily exposure of selected solubilizing cosolvents.](#)

[Table 3.2 Sucrose octaacetate aqueous solubility at 25 ± 0.2 °C after heatin...](#)

[Table 3.A.1 Injectable surfactants, solubilizing, emulsifying, and thickenin...](#)

Chapter 6

[Table 6.1 Adsorption isotherms](#)

Chapter 8

[Table 8.1 Sucrose octaacetate chemical kinetic observed first-order regressi...](#)

[Table 8.2 Sucrose octaacetate activation energy, extrapolated degradation ra...](#)

[Table 8.3 Typical peptide or protein degradation reactions.](#)

[Table 8.4 Beyond-use date for compounded preparations: selected examples.](#)

Chapter 9

[Table 9.1 Particle size diameter nomenclature.](#)

[Table 9.2 Different microscopic particle diameters.](#)

[Table 9.3 Particle size measuring technologies, their measurement principle,...](#)

[Table 9.4 Mechanisms for particle segregation \(Adapted from Mosby et al. 199...](#)

[Table 9.5 Grouped frequency table for particle size determination.](#)

[Table 9.6 Grouped frequency table for log normal particle size determination...](#)

[Table 9.7 Focused beam reflectance measurement chord length percentage in ea...](#)

[Table 9.8 Sieve granule weight percentage in each size interval.](#)

Chapter 11

[Table 11.1 QbD: guiding principles.](#)

[Table 11.2 Substances found in vaccines.](#)

Chapter 13

[Table 13.1 Advantages and disadvantages of tablets.](#)

[Table 13.2 Running powder manufacturing process steps.](#)

[Table 13.3 Advantages and disadvantages of running powder manufacturing proc...](#)

[Table 13.4 Solid-state physical properties and tablet implications.](#)

[Table 13.5 Solution-and solid-state chemical properties and tablet implicati...](#)

[Table 13.6 Tablet excipient classes and functions^a.](#)

[Table 13.7 Typical accelerated excipient compatibility stability protocol.](#)

[Table 13.8 Occupational exposure limits categorization and performance-based...](#)

[Table 13.9 Particle sizes obtained by various mills.](#)

[Table 13.10 Theoretical content uniformity based on a binominal distribution...](#)

[Table 13.11 Scale-up factors for V-blenders.](#)

[Table 13.12 Loss tangent and dielectric values for common pharmaceutical exc...](#)

[Table 13.13 Film-coating excipient classes and functions.](#)

[Table 13.14 Aqueous film-coating parameters.](#)

[Table 13.15 Permeability through selected packaging materials.](#)

[Table 13.16 Risk assessment for a wet granulated embossed film-coated tablet](#)

[Table 13.17 Risk control strategy for a wet granulated embossed film-coated ...](#)

[Table 13.18 NDA stability protocol.](#)

[Table 13.19 Reporting, identification, and qualification thresholds for degr...](#)

Chapter 14

[Table 14.1 Advantages and disadvantages of hard-shell capsules compared to t...](#)

[Table 14.2 Hard-shell capsule component classes and functions.](#)

[Table 14.3 Typical gelatin hard-shell capsule formulation.](#)

[Table 14.4 Typical hypromellose hard-shell capsule formulation.](#)

[Table 14.5 Typical pullulan hard-shell capsule formulation.](#)

[Table 14.6 Typical hard-shell starch capsule composition.](#)

[Table 14.7 Hard-shell capsule sizes and capacities.](#)

[Table 14.8 Intrinsic dissolution rates of common hard-shell capsule excipien...](#)

[Table 14.9 Lipid formulation classification system.](#)

[Table 14.10 Advantages and disadvantages of soft-shell capsules.](#)

[Table 14.11 Soft-shell capsule component classes and functions.](#)

[Table 14.12 Typical soft-shell gelatin capsule shell composition.](#)

[Table 14.13 Typical soft-shell starch capsule shell composition.](#)

[Table 14.14 Typical capsule stability NDA protocol.](#)

Chapter 15

[Table 15.1 Dispersed system classification based on the state of matter.](#)

[Table 15.2 Advantages and disadvantages of oral liquid coarse dispersed syst...](#)

[Table 15.3 Solid-state physical properties and dispersed system implications...](#)

[Table 15.4 Solution- and solid-state chemical properties and dispersed syste...](#)

[Table 15.5 Excipient classes and functions for liquid suspensions and solid ...](#)

[Table 15.6 Excipient classes and functions for macroemulsions and associatio...](#)

[Table 15.7 Topical emulsion formulation.](#)

[Table 15.8 Critical micelle concentration values for selected surfactants.](#)

[Table 15.9 Advantages and disadvantages of microemulsions.](#)

[Table 15.10 NDA stability protocol.](#)

[Table 15.A.1 Suspending, viscosity-enhancing, and structure-modifying agents...](#)

[Table 15.A.2 Sweetening agents.](#)

[Table 15.A.3 Flocculating agents and buffers.](#)

[Table 15.A.4 Emulsifying agents.](#)

[Table 15.A.5 Required HLB for oils and waxes.](#)

Chapter 16

[Table 16.1 Advantages and disadvantages of inhalation aerosols.](#)

[Table 16.2 Solid-state physical properties and aerosol implications.](#)

[Table 16.3 Solution and chemical properties and their aerosol implications....](#)

[Table 16.4 Excipient classes and function.](#)

[Table 16.5 Comparative advantages and disadvantages of conventional nebulize...](#)

[Table 16.6 Physical properties of HFA-134a and HFA-227.](#)

[Table 16.7 Advantages and disadvantages of aerosol drug delivery to the nose...](#)

[Table 16.8 Risk management matrix for orally inhaled and nasal drug products...](#)

[Table 16.9 Summary of FDA attribute tests for aerosols.](#)

[Table 16.10 NDA stability protocol.](#)

[Table 16.11 Reporting, identification, and qualification thresholds for degr...](#)

Chapter 17

[Table 17.1 Advantages and disadvantages of injectable dosage forms.](#)

[Table 17.2 Solid-state physical properties and injectable dosage implication...](#)

[Table 17.3 Solution- and solid-state chemical properties and injection dosag...](#)

[Table 17.4 Injectable excipient classes and functions.](#)

[Table 17.5 Antimicrobial preservatives.](#)

[Table 17.6 Standard oxidation potentials for various antioxidants^a.](#)

[Table 17.7 U.S.P. water monographs.](#)

[Table 17.8 U.S.P. particulate requirements for injectables.](#)

[Table 17.9 Dry heat sterilization and depyrogenation cycles.](#)

[Table 17.10 NDA stability protocol.](#)

Chapter 18

[Table 18.1 Advantages and disadvantages of topical ocular drug delivery.](#)

[Table 18.2 Ophthalmic excipient classes and functions.](#)

[Table 18.3 Composition of nepafenac ophthalmic suspension.](#)

[Table 18.4 Color coding recommended for topical ophthalmic medications.](#)

Chapter 19

[Table 19.1 Advantages and disadvantages of transdermal drug delivery.](#)

Chapter 20

[Table 20.1 Advantages and disadvantages of modified-release drug delivery.](#)

Chapter 27

[Table 27.1 Key differences between applications and DMFs.](#)

[Table 27.2 Application of the Q7 GMP guidance to API manufacturing.](#)

[Table 27.3 Good manufacturing practice guidance for APIs \(Q7\).](#)

Chapter 30

[Table 30.A.1 Conversion of animal doses to human equivalent doses based on b...](#)

[Table 30.A.2 Recommended duration of repeated-dose toxicity studies to suppo...](#)

[Table 30.A.3 Recommended duration of repeated-dose toxicity studies to suppo...](#)

[Table 30.A.4 Investigator and sponsor reporting responsibilities.](#)

List of Illustrations

Chapter 1

[Figure 1.1 Positive linear relationship between the concentration of aspirin...](#)

[Figure 1.2 Exponential decrease in drug blood concentration vs. time....](#)

[Figure 1.3 Linear relationship of the natural logarithm of drug blood...](#)

Chapter 3

[Figure 3.1 SOA drug-filter adsorption study. SOA mg/mL concentration after i...](#)

Chapter 7

[Figure 7.1 Newtonian flow: the rate of shear versus the shearing force.](#)

[Figure 7.2 Viscosity \(cP\) of some nonprescription products at room temperatu...](#)

[Figure 7.3 Rheogram depicting pseudoplastic flow. The y-axis is the shearing...](#)

[Figure 7.4 Rate of shear versus. shearing force for a dilatant material.](#)

[Figure 7.5 Plastic flow: the shearing rate versus shearing force.](#)

[Figure 7.6 Stress versus shear rate rheogram of \$W_1/O/W_2\$ multiple emulsion.](#)

[Figure 7.7 A compliance/creep rheogram of a \$W_1/O/W_2\$ multiple emulsion. A con...](#)

[Figure 7.8 Oscillatory \(dynamic\) frequency sweep curve showing the storage m...](#)

Chapter 8

[Figure 8.1 Sucrose octaacetate \(SOA\) concentration remaining versus time for...](#)

[Figure 8.2 Sucrose octaacetate \(SOA\) concentration remaining versus time for...](#)

[Figure 8.3 Arrhenius plots for the natural logarithm values of \$k_{obs}\$ as a fun...](#)

[Figure 8.4 Sucrose octaacetate pH-rate profiles of logarithm values of \$k_{extr}\$...](#)

Chapter 9

[Figure 9.1 Chord length and sieve particle size frequency polygon distributi...](#)

[Figure 9.2 Cumulative frequency percent plot of chord length and sieve parti...](#)

Chapter 12

[Figure 12.1 Product design interrelationships among formulation, process, an...](#)

[Figure 12.2 Drug development process.](#)

[Figure 12.3 Product design decision process following lead candidate selecti...](#)

Chapter 13

[Figure 13.1 Tablet formation sequence.](#)

[Figure 13.2 Molding for freeze-dried tablet.](#)

[Figure 13.3 Relationships among disintegration, dissolution, and absorption....](#)

[Figure 13.4 Rotary tablet press sequence.](#)

[Figure 13.5 Oscillating screen/low-shear granulator.](#)

[Figure 13.6 Plastic deformation engineering curve.](#)

[Figure 13.7 Cone mill.](#)

[Figure 13.8 Cone mill blade configuration.](#)

[Figure 13.9 Hammer mill.](#)

[Figure 13.10 Pin mill.](#)

[Figure 13.11 Fluid energy jet mill.](#)

[Figure 13.12 Fluid energy mill in self-contained clean-in-place isolator....](#)

[Figure 13.13 V-blender.](#)

[Figure 13.14 Conical screw mixer.](#)

[Figure 13.15 Gral high-shear granulator impeller and chopper.](#)

[Figure 13.16 Granulator bowl size and impeller-tip-speed relationship.](#)

[Figure 13.17 Defined areas within the roller compaction.](#)

[Figure 13.18 Fluid-bed granulator.](#)

[Figure 13.19 Compression-time profile.](#)

[Figure 13.20 Typical blister strip - top view \(a\) and blister pack - side vi...](#)

[Figure 13.21 Laminates for blister cavities \(a\) Duplex structure, \(b\) Triple...](#)

[Figure 13.22 Various lidding construction \(a\) Peelable foil construction, \(b...](#)

[Figure 13.23 Typical blister packaging assembly process.](#)

[Figure 13.A.1 Hygroscopicity classification system.](#)

Chapter 14

[Figure 14.1 Encapsulation using a semiautomated capsule machine.](#)

[Figure 14.2 Dosator sequence.](#)

[Figure 14.3 Dosing disk filling principle.](#)

[Figure 14.4 \$Cpk\$ evaluation for a 5-mg capsule % LC. LSL \(lower specification...](#)

[Figure 14.5 \$Cpk\$ evaluation for a 10-mg capsule % LC. LSL \(lower specificatio...](#)

[Figure 14.6 Rotary die process for soft gelatin capsules.](#)

Chapter 15

[Figure 15.1 DLVO energy interaction curve.](#)

[Figure 15.2 Mixer impellers.](#)

[Figure 15.3 High-shear mixer components.](#)

[Figure 15.4 Colloid mill.](#)

[Figure 15.5 Multiple emulsion.](#)

[Figure 15.6 Amphiphilic associations.](#)

[Figure 15.7 Liposome structures.](#)

[Figure 15.8 Phospholipids and cholesterol structures.](#)

[Figure 15.9 Taste score sheet.](#)

[Figure 15.10 Ishikawa diagram for formulation and manufacturing design of an...](#)

Chapter 16

[Figure 16.1 Respimat soft mist inhaler.](#)

[Figure 16.2 Metered-dose inhaler.](#)

[Figure 16.3 Metering valve \(inverted\).](#)

[Figure 16.4 Turbohaler.](#)

[Figure 16.5 The Diskus inhaler.](#)

[Figure 16.6 Response surface custom design and multicriteria optimization \(a...](#)

[Figure 16.7 Aerosol product design. Ishikawa fishbone cause and effect diagr...](#)

Chapter 17

[Figure 17.1 Freeze-drying cycle.](#)

[Figure 17.2 Freezing of a crystallizing system cycle.](#)

[Figure 17.3 Freezing of a noncrystallizing system.](#)

[Figure 17.4 Lyophilizer.](#)

[Figure 17.5 Steam autoclave.](#)

[Figure 17.6 Water vapor pressure-temperature profile.](#)

[Figure 17.7 Depyrogenation oven.](#)

Chapter 18

[Figure 18.1 Eye anatomy.](#)

[Figure 18.2 Sterile manufacturing process for brinzolamide ophthalmic suspen...](#)

Chapter 19

[Figure 19.1 Skin anatomy.](#)

[Figure 19.2 Steady-state flux.](#)

[Figure 19.3 Cumulative drug permeation.](#)

[Figure 19.4 Selected permeation enhancers.](#)

[Figure 19.5 Potent combination of penetration enhancers.](#)

[Figure 19.6 Various types of transdermal patch systems: \(a\) Reservoir patch,...](#)

[Figure 19.7 Schematic of an iontophoretic drug delivery system.](#)

[Figure 19.8 Schematic of the E-Trans iontophoretic system.](#)

Chapter 20

[Figure 20.1 Zero-order dissolution model.](#)